Results 111 to 120 of about 56,264 (258)

The role of neutrophils in the pathophysiology of inflammatory bowel diseases

Periodontology 2000, EarlyView.
Abstract Objectives Inflammatory bowel disease (IBD) encompasses a spectrum of chronic disorders of the gastrointestinal tract, with a potential bidirectional relationship with periodontitis. Neutrophils are key regulators of immune‐inflammatory responses and play a major role in both diseases.
Joao Paulo Steffens, Ekin Yay‐Kus, Rafael Scaf de Molon, Viorelia Stoica, Peter Rimmer, Josefine Hirschfeld, Asif Jilani Iqbal, Tariq Iqbal, Iain Chapple   +8 more
wiley   +1 more source

A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting

Therapeutics and Clinical Risk Management, 2008
Mark A Ware1, Paul Daeninck2, Vincent Maida31Pain Center, McGill University Health Center, Montréal, Quebec, Canada; 2Pain and Symptom Clinic, CancerCare Manitoba, Winnipeg, Manitoba, Canada; 3University of Toronto, Toronto, Ontario ...
Mark A Ware, Paul Daeninck, Vincent Maida   +2 more
doaj  

Chemotherapy-Induced Nausea and Vomiting #285 [PDF]

Journal of Palliative Medicine, 2014
Nishant, Tageja, Hunter, Groninger
openaire   +2 more sources

A Multi‐Institutional Retrospective Study of 21 Dogs Having Undergone Hypofractionated Radiotherapy for Adrenal Tumours (2017–2024)

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Radiation therapy (RT) has emerged as a promising non‐surgical approach for treating canine adrenal tumours. This multi‐institutional, retrospective study describes clinical outcomes for 21 dogs having been prescribed a course of hypofractionated image‐guided intensity‐modulated RT (IMRT) entailing delivery of 25–35 Gy total in 5 fractions ...
Yen‐Hao Erik Lai, Michael S. Kent, Michael W. Nolan, Dah‐Renn Fu, Jayme S. Looper   +4 more
wiley   +1 more source

A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis [PDF]

, 2017
Background: The prophylactic use of 5-HT3 receptor antagonists (setrons), after the first 24 h (acute phase) of exposure to emetic chemotherapy, to decrease the incidence of ‘delayed phase' emesis increases costs.
Aapro, M. S., Bernhard, J., de Pree, C., Maibach, R., Sessa, C., Thuerlimann, B.   +5 more
core  

Oxaliplatin‐induced neuropathy after total neoadjuvant therapy for rectal cancer: Dose–response relationship and impact on quality of life

International Journal of Cancer, Volume 159, Issue 1, Page 198-209, 1 July 2026.
What's New? Oxaliplatin serves a key role in the treatment of rectal cancer, though it is a significant cause of chemotherapy‐induced peripheral neuropathy. As total neoadjuvant therapy, in which all therapy is given before surgery, has become more common, understanding neuropathy has grown increasingly important. This study examined neuropathy and its
Georg W. Wurschi, Andreas Hinz, Melanie Schneider, Jan‐Niklas Becker, Bernd Frerker, Samuel M. Vorbach, Felix Ehret, Markus Diefenhardt, Fabian Schunn, Maria‐Elena von Gruben, Marcel Büttner, Elgin Hoffmann, Alexander Rühle, Josephine Beier, Simone Ferdinandus, Maike Trommer, Ezgi Ceren Sahin, Julian Hlouschek, Kynann Aninditha, Daphne Schepers von Ohlen, Justus Kaufmann, Alina Depardon, Hai Minh Ha, Christopher Kessler, Adrianna Cieslak, Simon Trommer, Alexander Fabian, Florian Rißner, Maximilian Römer, Klaus Pietschmann   +29 more
wiley   +1 more source

CPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Background/Objectives Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML.
Jonathan D. Bender, Lauren Pommert, Lori R. Backus, Andrea Bidwell, Courtney Blank, Erin H. Breese, Karen C. Burns, Adam Lane, Lynn H. Lee, Benjamin Mizukawa, Robin E. Norris, Maureen M. O'Brien, Daniel Peck, Christine Phillips, Thomas D. Ryan, Jennifer Young, Michael Absalon, John P. Perentesis   +17 more
wiley   +1 more source

Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation

MedComm – Oncology, Volume 5, Issue 2, June 2026.
The abnormal overexpression or gain‐of‐function mutations of EZH2 play a significant role in cancer occurrence and progression, highlighting the importance and potential of EZH2 as a cancer biomarker. Therefore, screening for effective and safe small‐molecule inhibitors, degraders, and natural compounds targeting EZH2 through preclinical cancer models ...
Xi Zhong, Jieni Li, Mingxuan Pan, Xiaoxue Ke, Hongjuan Cui   +4 more
wiley   +1 more source

Marked Bone Marrow Eosinophilia Post‐Azacitidine + Ivosidenib Treatment for Acute Myeloid Leukemia

International Journal of Laboratory Hematology, EarlyView.
Christopher Liwski, Curtis Marcoux, David M. Conrad   +2 more
wiley   +1 more source

Personalized Cancer Vaccines in the Clinical Trial Pipeline

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 362-368, June 2026.
ABSTRACT Aim To present an overview of personalized cancer vaccines currently undergoing clinical development, aiming to enhance awareness and promote collaboration among academic, commercial researchers, and non‐profit communities. Methods A dataset of 78 clinical trials for personalized cancer vaccines was generated using ClinicalTrials.gov database ...
Liudmila Iamukova, Elena Alferova
wiley   +1 more source